Humana Inc (HUM)
Health Care · Managed Health Care · US stock · S&P 500 component
$413.16
▼ -19.04 (4.41%)
Fair valueFair
$500 +21.1% to fair value
$250fair band $350–$650$751
Day's range
$411.77 – $432.40
52-week range
$161.90 – $456.50
About Humana Inc
Humana is a health insurer best known for its Medicare Advantage plans, which cover older Americans, and it also offers Medicaid, military and group plans. Its pharmacy and primary care clinic businesses support members. The company earns money from premiums paid mainly by government programmes, and profit depends on the gap between those premiums and the medical costs of its members.
The company reported trailing revenue of $137.2 billion and three-year growth of 11.8% a year. Profitability figures show an operating margin of 1.8% and a return on invested capital of 19%. On leverage, net debt to EBITDA is -2.6 times, so cash exceeds debt. The dividend yield is 0.6%. Its X-Ray Score is 50 out of 100. These figures describe past results and the present financial position only.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $161.90 – $456.50Volume 1,405,703Daily, split-adjusted
Vitals
Market cap$49.8B
52-week range$161.90 – $456.50
Volume (last day)1,405,703
P/E (TTM)44.1
EBIT / EV yield5.8%
Free-cash-flow yield2.6%
Dividend yield0.6%
Revenue (TTM)$137.2B
Net income (TTM)$1.1B
Operating margin1.8%
Return on capital18.9%
Debt incl. leases$14.0B
Cash & securities$22.0B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$500model spread $455 – $556
Fair
+21.1% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $413
Undervalued < $350Fair $350 – $650Overvalued > $650
10-year DCF (market-scaled)
$757
Peer multiples
$254
Earnings power floor (not blended)
$431
Fundamentals-adjusted multiple
$490
Growth the price implies
12.3%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
58/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield5.8%
Free-cash-flow yield2.6%
Fair value vs price1.2×
Growth
Weak
47/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)11.8%
EPS growth (3y)-23.6%
Growth consistency100%
Profitability
Weak
48/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital18.9%
Operating margin1.8%
Financial health
Fair
51/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA-2.6×
Interest cover3.7×
Dividends
Weak
47/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.6%
Dividends vs free cash flow25%
Dividend growth3.1%
Quarterly results: last 6 quarters
+10.4%
Dec '24
+8.4%
Mar '25
+9.6%
Jun '25
+11.1%
Sep '25
+11.3%
Dec '25
+23.5%
Mar '26
Revenue against the same quarter a year earlier. Latest quarter revenue $39.6B, diluted EPS $9.83.
Compare with peers
ELV Elevance Health, Inc.62 UNH Unitedhealth Group Inc59 CNC Centene Corp46Other Managed Health Care companies by X-Ray Score.
Fundamentals checklist
● 7 Good · ● 1 Average · ● 7 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldBad
Risk models
Altman Z''Good
Piotroski F-ScoreBad
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioAverage
Net debt / EBITDAGood
Interest coverBad
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalGood
Operating marginBad
Each check is graded against the company's sector, not a fixed number. Checklist score 46/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $83.1B | $92.9B | $106.4B | $117.8B | $129.7B |
| Operating income | $3.1B | $3.8B | $4.0B | $2.6B | $2.7B |
| Net income | $2.9B | $2.8B | $2.5B | $1.2B | $1.2B |
| Operating cash flow | $2.3B | $4.6B | $4.0B | $3.0B | $921M |
| Operating margin | 3.8% | 4.1% | 3.8% | 2.2% | 2.1% |
| Free cash flow | $920M | $3.5B | $3.0B | $2.4B | $375M |
| Diluted EPS | $22.67 | $22.08 | $20.00 | $9.98 | $9.84 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
10 bullish · 4 neutral · 2 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 415.0 | Bearish |
| EMA 10 | 414.9 | Bearish |
| SMA 20 | 399.0 | Bullish |
| EMA 20 | 406.4 | Bullish |
| SMA 50 | 393.9 | Bullish |
| EMA 50 | 393.8 | Bullish |
| SMA 100 | 383.1 | Bullish |
| EMA 100 | 369.4 | Bullish |
| SMA 200 | 300.4 | Bullish |
| EMA 200 | 331.8 | Bullish |
Oscillators (daily)
| RSI (14) | 54.26 | Neutral |
| MACD (12, 26) | 9.42 | Bullish |
| Momentum (12) | 8.28 | Bullish |
| Stochastic %K (14) | 46.25 | Neutral |
| Williams %R (14) | -53.75 | Neutral |
| CCI (20) | 71.54 | Neutral |
Pivot points (classic, last session)
S3 385.2 | S2 398.5 | S1 405.8 | Pivot 419.1 | R1 426.4 | R2 439.7 | R3 447.1 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.66 USD
Yield on today's price
0.64%
Frequency
Quarterly
Next ex-dividend date
30 Oct 2026
| Ex-dividend date | Amount per share |
|---|---|
| 30 Oct 2026 (upcoming) | 0.8850 |
| 26 Jun 2026 | 0.8850 |
| 27 Mar 2026 | 0.8850 |
| 26 Dec 2025 | 0.8850 |
| 26 Sep 2025 | 0.8850 |
| 27 Jun 2025 | 0.8850 |
| 28 Mar 2025 | 0.8850 |
| 31 Dec 2024 | 0.8850 |
| 30 Sep 2024 | 0.8850 |
| 28 Jun 2024 | 0.8850 |
| 27 Mar 2024 | 0.8850 |
| 28 Dec 2023 | 0.8850 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
HUM SEC filings
13 Oct 2026
8-KSEC EDGAR
Regulation FD disclosure
9 Oct 2026
8-KSEC EDGAR
Regulation FD disclosure
1 Sep 2026
8-KSEC EDGAR
Regulation FD disclosure
29 Jul 2026
10-QSEC EDGAR
Quarterly report
29 Jul 2026
8-KSEC EDGAR
Director or officer change
29 Jul 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
1 Jun 2026
8-KSEC EDGAR
Regulation FD disclosure
19 May 2026
8-KSEC EDGAR
Entered a material agreement
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.